Officers did their job and invested a bit. The street put $$$ to show confidence. It was now directors turn. Thanks mostly to Schimmel. Though, Sharp could have done better than 9300 shares. Directors knew in Nov. what they know now. Why didn't they buy them like CEO did?
In the past 4 months they have done everything right. Would they be able to sustain their momentum? If they could and if they raise another round of equity and push outstanding shares to 60M. At $50/a share. They will be valued at only $3B. I think it is fair compare to another company I have exposure to, ALXN. They have one drug and are valued at $15B.
I am out of shares now and waiting for an opportunity to get back in. The lower end of range may be in $12 now. But I have no illusion. ALNY is not going to go straight up. It will hit bumps and we may see lower prices.